Calithera Biosciences, Inc. (NASDAQ:CALA) Files An 8-K Submission of Matters to a Vote of Security Holders

Calithera Biosciences, Inc. (NASDAQ:CALA) Files An 8-K Submission of Matters to a Vote of Security Holders

Story continues below


Submission of Matters to a Vote of Security

On June 9, 2017, Calithera Biosciences, Inc. held its 2017 Annual
Meeting of Stockholders or the 2017 Annual Meeting at Embassy
Suites Hotel, 250 Gateway Boulevard, South San Francisco,
California 94080. At the 2017 Annual Meeting, our stockholders
voted on two proposals, each of which is described in more detail
in our definitive proxy statement on Schedule 14A filed with the
U.S. Securities and Exchange Commission on April 21, 2017. The
following is a brief description of each matter voted upon and
the results, including the number of votes cast for and against
each matter and, if applicable, the number of abstentions and
broker non-votes with respect to each matter. Proxies for the
2017 Annual Meeting were solicited to Section 14(a) of the
Securities Exchange Act of 1934, as amended, and there was no
solicitation in opposition of managements solicitation.

Proposal 1. Stockholders elected the two nominees for
ClassIII directors to serve until Calitheras 2020 Annual Meeting
of Stockholders or until his or her respective successor has been
duly elected and qualified. The voting results were as follows:

Director Name

Votes For VotesWithheld BrokerNon- Votes

Susan M. Molineaux, Ph.D.

22,692,883 3,118,155 5,647,370

H. Ward Wolff

22,665,808 3,145,230 5,647,370

Proposal 2. Stockholders ratified the selection by the
Audit Committee of the Board of Directors of Calithera of Ernst
Young LLP as Calitheras independent registered public accounting
firm for the year ending December31, 2017. The voting results
were as follows:

Votes For

Votes Against


Broker Non-



22,873 2,773

About Calithera Biosciences, Inc. (NASDAQ:CALA)

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells. Its lead product candidate, CB-839, is a critical enzyme in tumor cells. Its other product candidate, CB-1158, which is an enzyme that depletes the amino acid arginine, a key metabolic nutrient for T-cells. Its lead preclinical program in tumor immunology is directed at developing inhibitors of the enzyme arginase and may provide a therapeutic agent for the target. CB-839 is a selective, reversible and orally bioavailable inhibitor of human glutaminase. Hexokinase is an enzyme in the pathway that allows cancer cells to convert glucose to energy to fuel cancer cell growth.

An ad to help with our costs